FDA & Government News

FDA Approves Voranigo for Grade 2 IDH-Mutant Glioma

Share

  • 1

    Voranigo is the first FDA-approved drug for Grade 2 IDH-mutant glioma treatment.

  • 2

    Grade 2 IDH-mutant glioma is caused by mutations in the IDH gene family.

  • 3

    The incidence of Grade 2 IDH-mutant glioma in the U.S. is approximately 0.7 cases per 100,000 people.

  • 4

    The primary treatment option for Grade 2 IDH-mutant glioma has been surgical removal of the tumor.

  • 5

    Voranigo demonstrated a progression-free survival of 27.7 months in a late-stage clinical trial.

  • 6

    The placebo group had a progression-free survival of 11.1 months, indicating a significant improvement with voranigo.

Original Source(s)

FDA Approves Voranigo for Grade 2 IDH-Mutant Glioma

  • by Christy Santhosh

  • August 7, 2024

  • 1 min

Related Content

AI in Neuropathology: How Language Models Are Transforming Brain Tumor Diagnosis

New research explores how integrating AI with clinical guidelines can enhance diagnostic precision for complex brain tumors.

Mobile Phones Not Linked to Brain Cancer

WHO and global health bodies called for re-evaluation of the 2011 cancer risk classification.

Bladder Cancer Risk Markedly Elevated in MS

A nationwide French study of over 140,000 multiple sclerosis patients found a 71% increased risk of bladder cancer compared to the general population, with an even more pronounced risk in women with MS.